| P2093 | author name string | Hui Chen | |
| | Gang Ma | |
| | Xi Yang | |
| | Xiaoxi Lin | |
| | Lei Chang | |
| | Tianyou Wang | |
| | Yunbo Jin | |
| | Wenxin Yu | |
| | Yajing Qiu | |
| | Hanru Ying | |
| | Dongze Lv | |
| P2860 | cites work | Recent advances in laser therapy for the treatment of cutaneous vascular disorders | Q30812839 |
| | Infantile haemangioma: part II. Risks, complications and treatment | Q33898263 |
| | Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. | Q34034894 |
| | Propranolol targets the contractility of infantile haemangioma-derived pericytes. | Q34323894 |
| | Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation | Q34370676 |
| | Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment | Q34563146 |
| | A randomized, controlled trial of oral propranolol in infantile hemangioma. | Q34668015 |
| | Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells | Q36889161 |
| | Beta-blockers for the treatment of problematic hemangiomas | Q37476036 |
| | Pericyte-mediated regulation of capillary diameter: a component of neurovascular coupling in health and disease | Q37781281 |
| | Propranolol reduces infantile hemangioma volume and vessel density | Q38018191 |
| | Propranolol for infantile haemangioma: striking effect in the first weeks | Q38040224 |
| | Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis | Q38059089 |
| | How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient? | Q38172033 |
| | Diagnosis and management of infantile hemangiomas | Q38196581 |
| | Parotid tumors in children | Q40045626 |
| | Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases | Q40172521 |
| | Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis | Q43662652 |
| | Propranolol for treatment of ulcerated infantile hemangiomas. | Q43862792 |
| | Propranolol-resistant infantile haemangiomas. | Q44668179 |
| | More on propranolol for hemangiomas of infancy | Q46182923 |
| | Propranolol for severe hemangiomas of infancy. | Q46542573 |
| | Surgical management of parotid hemangioma | Q46783230 |
| | Parental experiences with propranolol versus oral corticosteroids for complicated infantile hemangioma, a retrospective questionnaire study | Q48141100 |
| | Late rebound of infantile hemangioma after cessation of oral propranolol. | Q51205703 |
| | Efficacy and safety of propranolol in the treatment of parotid hemangioma. | Q51502133 |
| | Management of parotid hemangioma in 100 children. | Q53906725 |
| | Hemangiomas of the parotid gland in children | Q66949769 |
| | Recurrence of infantile hemangiomas treated with propranolol | Q82499453 |
| | Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome | Q85088886 |
| | Treatment of infantile hemangiomas with propranolol: clinical guidelines | Q86975176 |
| | Recurrence of infantile hemangioma after termination of propranolol treatment | Q87062719 |
| P304 | page(s) | E1730-6 | |
| P577 | publication date | 2015-12-17 | |
| P1433 | published in | Head & Neck | Q13703062 |
| P1476 | title | Use of propranolol for parotid hemangioma. | |
| P478 | volume | 38 Suppl 1 | |